Retour

Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

Health Health

Topline data from Phase 2b trial of Descartes-08 in myasthenia gravis remains on track for mid-2024 Topline data from Phase 2b trial of Descartes-08 in myasthenia gravis remains on track for mid-2024

GlobeNewswire Inc. • 22/05/2024 à 13:00:00
Cartesian Therapeutics, Inc. Common Stock
Address: 65 GROVE STREET
Postal Code: 02472
City: WATERTOWN
State: MA
Phone Number: 617-923-1400
Website: https://www.cartesiantherapeutics.com
Status: Active
Company Info

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

List Date2016-06-22
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001453687
Composite figiBBG001J19Q25
Share Class figiBBG001V0FQQ0
Market Cap407,351,653 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees38
Share Class Shares Outstanding17800000
Weighted Shares Outstanding17796053
Round Lot100
Updated date2024-06-21
Stats
Last 5 days
21-06
20-06
18-06
17-06
14-06
Last
22.93
23.062
22.055
24.655
27.28
Variance
-0.06%
4.57%
-10.16%
-9.62%
-6.48%
Open
22.944
22.055
24.55
27.28
29.17
Highest
24.44
24.512
24.55
27.364
29.94
Lowest
24.439
24.46
24.026
27.28
29.3
History
PeriodVarhighestlowest
1 week
-15.95%
27.364
24.026
1 month
-6.15%
26.585
24.026
3 month
2925.07%
0.801
0.519
6 month
3084.72%
0.73
0.519
1 year
2743.15%
1.07
0.519
3 year
2743.15%
1.07
0.519
5 year
2743.15%
1.07
0.519
10 year
2743.15%
1.07
0.519
Calendar
21 June 2024 (Time UTC) Actual Previous Consensus
15:30
United States
-25000.000
15:30
United States
-56300.000
15:30
United States
51700.000
15:30
United States
-111400.000
15:30
United States
-102800.000
★★
15:30
United States
-8000.000
15:30
United States
233900.000
15:30
United States
233500.000
15:30
United States
-101000.000
15:30
United States
61300.000
15:30
United States
1100.000
13:00
United States
JUN 21
485.000
488.000
★★
13:00
United States
JUN 21
588.000
590.000
★★★
11:00
United States
10:30
United States
JUN 14
71000000000.000
74000000000.000
69000000000.000
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:RNAC1240621P00007500 OPASPN Put American 100 7.5 BATO 2024-06-21
O:RNAC1240621P00005000 OPASPN Put American 100 5 BATO 2024-06-21
O:RNAC1240621P00002500 OPASPN Put American 100 2.5 BATO 2024-06-21
O:RNAC1240621C00007500 OCASPN Call American 100 7.5 BATO 2024-06-21
O:RNAC1240621C00005000 OCASPN Call American 100 5 BATO 2024-06-21
O:RNAC1240621C00002500 OCASPN Call American 100 2.5 BATO 2024-06-21
O:RNAC240621P00007500 OPASPS Put American 100 7.5 BATO 2024-06-21
O:RNAC240621P00005000 OPASPS Put American 100 5 BATO 2024-06-21
O:RNAC240621P00002500 OPASPS Put American 100 2.5 BATO 2024-06-21
O:RNAC240621C00007500 OCASPS Call American 100 7.5 BATO 2024-06-21
O:RNAC240621C00005000 OCASPS Call American 100 5 BATO 2024-06-21
O:RNAC240621C00002500 OCASPS Call American 100 2.5 BATO 2024-06-21
O:RNAC2240621P00007500 OPASPN Put American 3 7.5 BATO 2024-06-21
O:RNAC2240621P00005000 OPASPN Put American 3 5 BATO 2024-06-21
O:RNAC2240621P00002500 OPASPN Put American 3 2.5 BATO 2024-06-21
O:RNAC2240621C00007500 OCASPN Call American 3 7.5 BATO 2024-06-21
O:RNAC2240621C00005000 OCASPN Call American 3 5 BATO 2024-06-21
O:RNAC2240621C00002500 OCASPN Call American 3 2.5 BATO 2024-06-21
O:RNAC240517P00007500 OPASPS Put American 100 7.5 BATO 2024-05-17
O:RNAC240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:RNAC240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:RNAC240517C00007500 OCASPS Call American 100 7.5 BATO 2024-05-17
O:RNAC240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:RNAC240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:RNAC240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:RNAC240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:RNAC240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:RNAC240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:RNAC240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:RNAC240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:RNAC2240419P00007500 OPASPN Put American 3 7.5 BATO 2024-04-19
O:RNAC2240419P00005000 OPASPN Put American 3 5 BATO 2024-04-19
O:RNAC2240419P00002500 OPASPN Put American 3 2.5 BATO 2024-04-19
O:RNAC2240419C00007500 OCASPN Call American 3 7.5 BATO 2024-04-19
O:RNAC2240419C00005000 OCASPN Call American 3 5 BATO 2024-04-19
O:RNAC2240419C00002500 OCASPN Call American 3 2.5 BATO 2024-04-19
O:RNAC240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:RNAC240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:RNAC240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:RNAC240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:RNAC240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:RNAC240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:RNAC1240315P00007500 OPASPN Put American 100 7.5 BATO 2024-03-15
O:RNAC1240315P00005000 OPASPN Put American 100 5 BATO 2024-03-15
O:RNAC1240315P00002500 OPASPN Put American 100 2.5 BATO 2024-03-15
O:RNAC1240315C00007500 OCASPN Call American 100 7.5 BATO 2024-03-15
O:RNAC1240315C00005000 OCASPN Call American 100 5 BATO 2024-03-15
O:RNAC1240315C00002500 OCASPN Call American 100 2.5 BATO 2024-03-15
O:RNAC240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:RNAC240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:RNAC240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:RNAC240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:RNAC240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:RNAC240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:RNAC1240119P00007500 OPASPN Put American 100 7.5 BATO 2024-01-19
O:RNAC1240119P00005000 OPASPN Put American 100 5 BATO 2024-01-19
O:RNAC1240119P00002500 OPASPN Put American 100 2.5 BATO 2024-01-19
O:RNAC1240119C00007500 OCASPN Call American 100 7.5 BATO 2024-01-19
O:RNAC1240119C00005000 OCASPN Call American 100 5 BATO 2024-01-19
O:RNAC240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:RNAC1240119C00002500 OCASPN Call American 100 2.5 BATO 2024-01-19
O:RNAC240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:RNAC240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:RNAC240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:RNAC240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:RNAC240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
News Stream
Stocks Changes in company's own shares
GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to a new employee. On June 3, 2024, the Company issued to this employee an option to purchase 11,000 shares of the Company’s common stock with an exercise price of $36.00, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company’s board of directors. The option vests as to 25% on June 3, 2025, and then in three equal annual installments thereafter such that the option will be fully vested on June 3, 2028. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee’s entry into employment with the Company.
GlobeNewswire Inc. • 2w ago
Health Health
Topline data from Phase 2b trial of Descartes-08 in myasthenia gravis remains on track for mid-2024 Topline data from Phase 2b trial of Descartes-08 in myasthenia gravis remains on track for mid-2024
GlobeNewswire Inc. • 1mo ago
Calendar Calendar of Events
GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024, at 3:00 p.m. ET.
GlobeNewswire Inc. • 1mo ago
Stocks Earnings Releases and Operating Results
Topline data from Phase 2b trial of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis on track for mid-2024
GlobeNewswire Inc. • 1mo ago
News News
Cartesian Therapeutics, Inc. (RNAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks Investment Research • 2mo ago
Stocks Changes in company's own shares
Proposals approved at Company’s special meeting of stockholders held March 27, 2024 Proposals approved at Company’s special meeting of stockholders held March 27, 2024
GlobeNewswire Inc. • 2mo ago
News News
Cartesian Therapeutics, Inc. (RNAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks Investment Research • 3mo ago
Calendar Calendar of Events
GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in March:
GlobeNewswire Inc. • 3mo ago
Stocks Major shareholder announcements
GAITHERSBURG, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to a new employee. On March 1, 2024, the Company issued to this employee an option to purchase 375,000 shares of the Company’s common stock with an exercise price of $0.69, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. This option was granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company’s board of directors. The option vests as to 25% on March 1, 2025, and then in three equal installments thereafter such that the option will be fully vested on March 1, 2028. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee’s entry into employment with the Company.
GlobeNewswire Inc. • 3mo ago
Health Health
New facility expected to support expanded cGMP manufacturing of clinical and commercial supply of Company’s pipeline of mRNA cell therapies for the treatment of autoimmune diseases
GlobeNewswire Inc. • 3mo ago
See All
Related

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT